Vanguard Group Inc. Trims Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Vanguard Group Inc. lessened its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,314,372 shares of the specialty pharmaceutical company's stock after selling 33,739 shares during the period. Vanguard Group Inc. owned about 6.25% of ANI Pharmaceuticals worth $72,658,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Exchange Traded Concepts LLC increased its holdings in ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock worth $684,000 after purchasing an additional 310 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after buying an additional 412 shares during the last quarter. Natixis Advisors LLC grew its holdings in ANI Pharmaceuticals by 2.3% during the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after buying an additional 417 shares in the last quarter. US Bancorp DE raised its position in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares during the last quarter. Finally, KBC Group NV lifted its stake in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Remove Ads

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company's stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock worth $197,792. Company insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded up $0.05 during mid-day trading on Tuesday, hitting $68.77. The stock had a trading volume of 97,504 shares, compared to its average volume of 292,973. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business has a fifty day moving average price of $62.52 and a 200-day moving average price of $59.15. The firm has a market cap of $1.50 billion, a P/E ratio of -125.04 and a beta of 0.49.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several recent analyst reports. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Friday. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective for the company. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. StockNews.com downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, April 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $79.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.